Developing Novel ADCs to treat high burden diseases

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer, with new payloads to address cancer resistance mechanisms.

The company is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development.

Adcytherix is backed by a syndicate of leading life science investors including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR).